Latest Breaking News On - வேகமாக டிராக் நிலை - Page 1 : comparemela.com

- Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO, CA, May 5, 2021 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the first quarter ended March 31, 2021. NUPLAZID delivered strong year-over-year performance in the first quarter of 2021. Looking ahead, we see positive signs in the Parkinson s disease psychosis market supporting revenue growth for the remainder of the year as we anticipate continued improvements in the conditions related to the pandemic, said Steve Davis, Chief Executive Officer. Furthermore, we look forward to a Type A meeting with the FDA to discuss an approval path for pimavanserin in dementia-related psychosis and we continue to advance our two Phase 3 programs for Rett syndrome and the negative symptoms of schizophrenia, as well as our Phase 2 pain program and earlier pipeline opportunities.

United statesSteve davisMark johnsonEric endicottCompany updatesDrug administrationExchange commissionAcadia pharmaceuticalsVanderbilt universityAcadia pharmaceuticals incChief executiveComplete response letterNew drug applicationWebcast informationFast track statusOrphan drug designation